The facts behind Reta
Retatrutide, often called “Reta,” is an investigational triple-agonist weight-loss drug. Early trials look impressive, but the main questions are long-term safety, tolerability, and what happens outside tightly run studies.
Tag
Pages related to Clinical.
Retatrutide, often called “Reta,” is an investigational triple-agonist weight-loss drug. Early trials look impressive, but the main questions are long-term safety, tolerability, and what happens outside tightly run studies.
A long-acting, synthetic dual agonist of the GLP-1 and GIP receptors, used clinically for type 2 diabetes and obesity.
A synthetic form of gonadotropin-releasing hormone (GnRH), an upstream hypothalamic signal in the reproductive hormone axis.
A family of neuropeptides (KISS1-derived) that strongly stimulate the reproductive hormone axis upstream of GnRH, studied in reproductive physiology and clinical fertility contexts.
A somatostatin receptor targeting peptide (octreotate derivative) used as the targeting component in peptide receptor radionuclide therapy (PRRT), including 177Lu-DOTATATE for neuroendocrine tumors.
A GLP-2 analog peptide drug used in short bowel syndrome to improve intestinal absorption and reduce parenteral support needs in some patients.
An endogenous gut hormone peptide that signals through the GLP-1 receptor and forms the biological basis for GLP-1 receptor agonist drugs used in diabetes and obesity.
A new observational study links GLP‑1 therapy to lower atrial fibrillation risk even when people do not lose weight, with the strongest signal reported for semaglutide.
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
A new meta-analysis pools one-year results for vosoritide in children with achondroplasia, clarifying typical growth changes and the most common side effects.
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
An open-access meta-analysis reports higher odds of depression-related adverse events among GLP-1 receptor agonist users (OR 1.49), but between-study heterogeneity is extreme (I² ~99%), which limits how literally the pooled number should be taken.
A post hoc analysis of SURPASS-CVOT expands the endpoint list beyond classic MACE. In patients with type 2 diabetes and established CVD, tirzepatide was associated with fewer composite cardiovascular + kidney events than dulaglutide, with more GI side effects.
A new randomized-trial meta-analysis (preprint) finds the ‘hard outcome’ signal in heart failure is not clean, but people with HFpEF and obesity report better symptoms and walk a bit farther on GLP‑1 drugs.
A living meta-analysis of placebo-controlled RCTs of semaglutide and tirzepatide lands near ‘no signal’ for acute pancreatitis. That’s reassuring, but rare-event uncertainty is exactly why this concern keeps coming back.
A meta-analysis comparing bariatric surgery with GLP‑1 drugs found the gap widened as follow-up got longer. The signal is strong, but still confounded by non-random treatment selection and real-world access differences.
A 2026 review of glucagon-like peptide therapies in short bowel syndrome puts the spotlight where patients live: side effects, monitoring, and the trade-offs that come with reducing dependence on IV nutrition.
A nationwide multicenter retrospective study from Japan (422 patients, 33 institutions) reports real‑world outcomes for 177Lu‑DOTATATE PRRT in advanced neuroendocrine neoplasms. Response and progression-free survival look broadly consistent with PRRT’s established role, with useful predictor breakdowns.